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Editorial
Wrap-Up…and Regroup!
By David B. Nash, MD, MBA
Editor-In-Chief

This issue marks 2 important transitions
in the 6-year history of Prescriptions for
Excellence. The first is that our 3-part series
on health care organization governance
has come to an end. Collectively, the
articles in the series validate my initial
editorial comment1 that “governance is
risky business” and provide an up-to-date
tutorial on this multidimensional topic.
Judging from the feedback I’ve received,
including requests for additional copies,
many readers agree.
As those who know me can attest, I am
a huge proponent of disseminating print
material via hard copy. For me, referring
someone to a Web site doesn’t have the
same cachet as handing him or her a
tangible item. So it is with mixed feelings
that I announce the second transition.
Beginning with the Fall 2013 issue,
Prescriptions for Excellence will transition
into a digital publication. Readers can rest
assured that the timeliness, applicability,
and quality of the content will continue
at the same high level.
Before wrapping up the topic of
governance, I’d like to touch on an aspect
that may be an uncomfortable topic
for physician leaders — specifically,

the governance risks associated with
confidentiality, conflicts of interest,
and related fiduciary issues. As hospital
and health system boards respond to
the Affordable Care Act’s (ACA) call
for integrated strategies, boards must
be particularly sensitive to these areas.
Consider the following scenario:
Acting in response to the ACA, a
medical center’s governing board meets
to formulate a plan for incorporating an
accountable care organization (ACO)
and a patient-centered medical home
(PCMH). Sitting on the board are 6
physician members of the center’s medical
staff, 2 of whom have relationships with
competing provider organizations (eg,
imaging laboratory). One discloses the
relationship and recuses herself from
confidential discussions pertaining to
the particular service. The other secretly
Prescriptions for Excellence in Health
Care is brought to Population Health
Matters readers by Jefferson School
of Population Health in partnership
with Lilly USA, LLC to provide
essential information from the quality
improvement and patient safety arenas.

(continued on page 2)
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transmits confidential information to
the competing organization, thereby
undermining the medical center’s
integration efforts.
Although hypothetical, the scenario
isn’t as far-fetched as it sounds. In fact,
the authors who created it reported
disturbingly similar events that had
occurred, one of which led to a 1995
California jury award of nearly $14
million in damages to a hospital in a
lawsuit against 2 former physicians who
were alleged to have similarly exploited
their governing board positions to build
their own competing facilities and steer
patients to them.2
Physician directors make vitally
important governance contributions
to health care organizations. However,
when governing boards consider new
proprietary strategic integration models,
a physician director is in a potentially
difficult position if discussions involve his
or her medical practice and/or business.

Boards that anticipate such risks
and take a proactive approach can
minimize the potentially adverse
effects of such biases or other conflicts
of interest. The authors suggest a
formal plan that includes: general
board education on applicable state
law regarding the director’s duty of
loyalty, targeted briefing of the board’s
conflicts committee and of physician
directors on the potential issues arising
from consideration of integrationbased strategies, careful monitoring
of board and committee agendas to
identify sensitive discussion items in
advance, making the hospital’s legal
counsel available to physician directors
for consultation on specific issues,
and assisting the board’s conflicts
committee to resolve disclosed
potential issues (eg, adopting specific
conflicts management plans).
I’ll close with kudos to the authors
in this issue who shared their keen
insights into governance in 4 key areas:

the continuing impact of the ACA on
governance (“Governance Implications of
the Affordable Care Act and Other Health
Care Trends”), governance in large health
systems (“Using Quality and Safety aD ta
for Board Engagement That Makes a
iD fference in Patients’ Lives”), the impact
of external forces on governance (“The
Future of Governance: Health Care Boards
Change with Challenging Times”), and an
enlightening study of governing boards
(“Board Size and Composition in Large
Nonprofit Health Systems”) that reveals
both how far we’ve come and how far
we have yet to go.
As always, I welcome feedback from
our readers at david.nash@jefferson.edu.
References
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A Message from Lilly
Sustaining Medical Innovation in a Time of Rapid Reform
By Alex M. Azar II

Among the insightful perspectives
in this issue of Prescriptions for
Excellence, perhaps none is more
important than the need for
governance boards to look forward
— particularly as the hospitals and
health systems they oversee drive
significant shifts in our national
health care landscape. In surveying
the future, we must not lose sight of
one of the vital drivers of improving
long-term patient outcomes: the
pursuit of medical innovation.

While much of this discussion lies
at the federal policy level, much also
rests in the hands of the growing
number of state health insurance
exchanges (HIE), integrated health
systems, and accountable care
organizations across the United
States. Washington’s reforms may
have accelerated the pace of change,
but it will be up to individual systems
— and, by nature, their governing
boards — to bring them to life for the
advancement of quality patient care.

As Barry Bader writes in an
article that follows, “Success under
the incentives of reform will be
determined by how hospitals and
health systems redesign care delivery
in order to drive down spending and
improve outcomes.” In doing so,
we must not harm the health care
ecosystem that has so crucially fostered
innovation — and with it, improved
outcomes — over the long term.
In my former role as Deputy
Secretary of Health and Human
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Services, I often met with my
counterparts in the health
ministries of other countries, and
I found my position unique. Like
the others, I was responsible for
the financing and delivery of health
care. But my portfolio also included
innovation — most notably,
oversight of the National Institutes
of Health and the Food and Drug
Administration (FDA).
Unlike my colleagues, I had to
balance the goals of reducing costs
and sustaining innovation. This
broader perspective also helped
me appreciate the potential for
innovation to reduce costs, improve
quality, and allay suffering. As we
struggle with the challenges of
health care, a narrow focus on costs
to the exclusion of innovation would
be self-defeating.
What we need is a different
perspective on the value of medical
innovation and an understanding
of what it will take to increase
that value in the years ahead to
improve our collective “ROI” —
Return on Innovation.
Medical innovation over the past
century transformed the basic
expectations of human life that
had prevailed since the dawn of
civilization. Tens of millions of
death sentences were lifted, and
once-dreaded diseases became
manageable chronic conditions.
Consider our progress against 2
leading killers:
• Coronary heart disease (CHD):
The death rate from CHD in
the United States has declined
by about two thirds since it

peaked in 1968.1 There were 1.7
million more Americans alive
last year who would have died at
the 1960s’ rate.2
• Cancer: The American Cancer
Society states that, from 1991
to 2009, the death rate for all
cancers dropped 20%. That’s 1.2
million people who did not die
from cancer.3
The cumulative impact of the medical
innovation of the past century is
nothing short of mind-boggling.
In 1900, the average American life
expectancy was age 47, and in 2000,
it was age 78 — an unprecedented
increase of 66% in 1 century!
The biopharmaceutical industry is a
big reason we’ve gained these extra
decades. An analysis by Columbia
University Professor Frank
Lichtenberg found that launches of
new medicines accounted for 40%
of the increase in life expectancy
during the 1980s and 1990s alone.4
We all know people in their 70s
— and even 80s — who have left
behind rocking chairs for sea kayaks
and cross-country skis and, while
we’re all frustrated with the rise
in overall health care spending, a
big chunk of it is due to the fact
that these folks are now healthy
enough to get knee replacements or
coronary artery bypasses or cancer
treatments and continue their active
lifestyles, which sounds a lot better
than the alternative to me.
But we must ask: As we reform our
health care system, are we building
a new foundation that will make the
breakthroughs of tomorrow possible?

3

The pursuit of innovation in any field
is a difficult, high-risk venture. If
innovation is to take root and grow,
it requires a combination of elements
we describe as an “ecosystem.” The
health of the ecosystem starts with
open access to health care markets
with market-based pricing. For
example, we believe that doctors and
patients must remain the ones to
choose, in an informed way, from all
available treatment alternatives.
My message is simple: A myopic
focus on cost control impacts
prices, prices affect investment,
investment affects innovation, and
innovation affects quality of health
outcomes. Innovation and freedom
of competition play a critical role
in our health care economies, and
misguided — albeit well-intentioned
— government and institutional
policies can greatly stunt its growth.
Without question, the tension
between meeting rising costs
and investing in innovations for
tomorrow is one of the most
intractable questions political
leaders face. Consider the European
experience. Often, in trying to
strike this balance, European policy
makers lean too much toward shortterm savings and succumb to the
temptation to control expenditures
through direct price controls, cuts in
reimbursement rates, delayed market
access, and other subtle and not-sosubtle practices that either restrict
the amounts paid for innovative
products or reduce consumption of
innovative medicines and devices.
Unfortunately, these trends have
recently spread across the Atlantic
and are rearing their heads in
(continued on page 4)
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our commercial and government
systems here in the United States
with disturbing frequency.
Why does this matter? Because
there is a direct relationship between
these types of cost containment
measures and innovation. A study
by the US Commerce Department
evaluated cost controls in a number
of industrialized countries and
found that lifting cost controls
could increase revenues for patented
medicines by as much as $18
billion to $27 billion annually —
something that would greatly foster
innovation.5 This translates into as
much as $5-$8 billion of lost global
research and development as a result
of cost controls.
Rather than looking at cost as
the only driver of value, we must
implement market-based solutions
to sustain innovation in the future.
Consumers are served best by
free, strong competition that
creates choices, better prices, and
broader benefits while encouraging
sustainable innovation.
Contrast the European experience
with our own great American
experiment with Medicare Part D
— the only part of our governmentsponsored health care system that
does not have the distortion of price
controls. Part D has been a bigger
win than even those of us who
helped launch it imagined. Costs
have been 40% below the original
Congressional Budget Office
estimate, and beneficiaries report a
90% satisfaction rate.6
As HIEs resulting from the
Affordable Care Act launch later

this year, we should be looking
to Part D for learnings to foster
maximum competition. When you
have a competitive health insurance
market, with a well-informed
beneficiary in the driver’s seat making
choices rather than bureaucrats,
the value of the medicine — and
innovation — is preserved.
If the sole impact of biopharmaceutical
innovation was additional decades
of life and health, we’d be hardpressed to find its equal. There’s also
compelling evidence that innovative
medicines are the most cost-effective
part of health care. A couple years
ago, former Medco CEO David
Snow visited Lilly and reported
that it costs half as much to treat
patients with diabetes who adhered
to their prescribed course of medicine
compared to those who didn’t.
Medicines are not cost drivers, they’re
cost savers. In 2011, the Journal of the
American Medical Association reported
that when seniors who didn’t have
comprehensive prescription drug
coverage received coverage through
Medicare Part D, they saved an
average of $1200 per year in hospital,
nursing home, and other medical
costs.7 That translates into $12 billion
per year in savings across Medicare.8
David Snow summed it up well:
“Drugs used properly are part of the
solution, not part of the problem.”
Some people will still say that we
have all the innovation we need
or that, in this difficult economic
climate, we just can’t afford it. But
we must build upon — not rest
upon — the contributions of the
past. For all our tremendous progress,
much more remains to be done.

With 10,000 American baby
boomers turning 65 every day, it’s
not surprising that we’re seeing a
sharp increase in the incidence of
diseases associated with aging (eg,
cancer, type 2 diabetes, osteoporosis,
neurodegenerative diseases). The
Alzheimer’s Association estimates
that by 2050 — absent effective
treatments — the number of
Americans over age 65 who develop
Alzheimer’s will triple to 13.8
million, and costs in the United
States alone could rise to $1.2
trillion a year.9
Let’s face it: The only way to
make further inroads against these
and other conditions is to sustain
medical innovation. The good news
is that advances in the life sciences
are bringing treatments, once
beyond our reach, finally into view.
One need look no further than the
35 new molecular entities approved
by FDA in 2012.
But we can’t stop the revolution
cold in its steps as our health care
system continues down the path
of rapid reform. Clearly, when it
comes to sustaining innovation, the
burden remains on research-based
companies like Lilly — as it should.
Businesses that live or die by health
care innovation ask only that we be
allowed to continue doing just that:
Proving the value of what we’ve
developed … and succeeding or
failing in the marketplace.
It is impossible to predict the
full range of benefits that future
generations could enjoy from today’s
innovation, but when I think of the
incredible advances in medicine
over the past century, I’m convinced

This newsletter was jointly developed and subject to editorial review by Jefferson School of Population Health and Lilly USA, LLC, and is supported through funding by Lilly USA, LLC.

Prescriptions for Excellence in Health Care

that what might seem unimaginable
today will be commonplace
tomorrow. For example:
• treatments that transform cancer
into a chronic disease, with
survival times measured in decades
rather than months,
• effective treatments for malaria,
tuberculosis, and other diseases
affecting tens of millions in the
developing world,
• breakthroughs that will save
millions from the devastation of
Alzheimer’s disease,
• cardiovascular repair and
prevention of heart disease,
• replacement organs, and,
ultimately,

• additional healthy, productive
years for people to enjoy life with
enhanced vitality.
As members of health care governance
boards grapple with cost and quality
questions, I hope they too will
conclude that innovation is not the
problem. Innovation is the solution —
the essential key to ensuring that our
ecosystem remains healthy and viable
to deliver improved patient outcomes
for years to come.
Alex M. Azar II is the President of Lilly
USA, LLC, the U.S. affiliate of Eli Lilly
and Company, and is a former eD puty
Secretary of Health and Human Services.
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Governance Implications of the Affordable Care Act and Other Health Care Trends
By Barry S. Bader
As much as hospitals and health systems
have grown and changed over the past
several decades, their governance has
tended to retain many traits from their
roots. These often include recruiting
trustees from the local community’s
business and finance elite, limiting what
is expected from volunteers, measuring
performance mainly in the acute care
setting, and allocating “representation” to
a semiautonomous medical staff.

changes in the governance of not-forprofit hospitals and health systems:

In recent years, however, several powerful
forces have necessitated significant

• Recognition that, in this era of
industry aggregation (ie, spread

• Higher expectations for corporate
accountability and director
professionalism are requiring
boards to be more accountable,
independent, and transparent, and
to follow “best practices” such as
competency-based selection to
optimize their effectiveness.

of multihospital systems, and
increasing economic alignment of
hospitals and physicians), boards
are governing large, complex,
diversified organizations that require
optimization of system-wide rather
than silo performance to be successful.
• Heightened scrutiny of tax exempt
organizations by Congress, the
Internal Revenue Service (IRS),
state governments, and the courts
means not-for-profit boards can
no longer take their tax status for
(continued on page 6)
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granted. They must be prepared to
demonstrate their organizations’
community benefit, responsible
stewardship, and ethical conduct to
“earn” their tax breaks.
Looking ahead, the reduced
reimbursements, value-based payment
methods and quality incentives
embodied in the Affordable Care
Act and embraced by private payers
are expected to drive further industry
aggregation and performance
improvement. Success under the
incentives of reform will be determined
by how hospitals and health systems
redesign care delivery in order to drive
down spending and improve outcomes.
These organizations must transform
into high-performing, integrated
delivery systems that are accountable
for their costs and quality across the
full continuum of care.
Three Structural Models of Future Care
System Governance
Each hospital and health system must
undertake a candid self-examination of
its governance. Are there certain hospitalrooted roles, structures, and practices
that once were strengths but that could
be impediments to high-performing
care system governance? Are current
structures and practices sufficiently
robust to evolve as the delivery system
transforms or does the governance model
require a complete overhaul?
It may be useful for boards to think
about 3 emerging governance models,
described in a recent survey of health
system leaders by the American Society
for Healthcare Strategic Planning and
Marketing and the American College
of Healthcare Executives. The models
reflect different core properties of
various care systems (Figure 1).
Professional Governance Model:
Organizations that see themselves as

Figure 1. Three Emerging Care System
Governance Models

Source: American Society for Healthcare Strategic Planning and
Marketing and the American College of Healthcare Executives.

a “health company” (ie, not-for-profit
in motive but possessing the culture of
a customer-focused, high-performing
corporate enterprise) may adopt this
model wherein governance is viewed
as a “professional commitment” of
the highest order by hard-working
directors as in the best corporate
boards. Whether compensated or
not, such boards impose higher
expectations on directors’ performance
than the typical volunteer board.
Directors are recruited wherever
the best talent resides — locally or
outside the communities served. Board
composition is based on exceptional
competence in needed skills and
independence (ie, no material conflicts
of interest).
Organizationally, such boards have
a lean approach to size, committee
structure, and meeting frequency —
all intended to drive a collaborative
team culture of high-performing,
independent, and accountable
governance. A single parent board
has unquestioned authority; local
subsidiary boards, if retained, serve
in advisory roles although large,
multistate care systems may retain
regional governing bodies with
delegated authority and responsibility.

Clinical Enterprise Governance: This
model is designed for organizations that
view themselves as primarily clinical
enterprises that are physician-driven,
professionally managed, and patientcentered. Medical and professional
staff are employed or under contract,
and clinical services are comanaged by
“dyads” of physician and nonphysician
leaders such as nurse executives.
Governance often involves 2 boards that
have clearly delineated authority and
roles. A corporate parent or foundation
board has ultimate decision-making
authority and focuses on high-level
strategy, goal setting, and independent
oversight. An empowered and active
clinical enterprise board of senior
executives and senior physician and
nursing leaders is the engine for
delivery system leadership that is fully
accountable to the parent board for
the patient experience, clinical quality,
financial results, and clinical operations.
In addition to the chief executive
officer (CEO) and chief medical
officer, the parent board includes
predominantly, or all, independent
directors. As in the Professional
Governance Model, local and outside
parent board directors are selected
mainly on the basis of needed
competencies.
Enhanced, Community-based
Governance: Organizations that see
themselves primarily as integrally
connected to and serving mainly their
local communities retain a community
flavor in their board composition and
its scope of work; however, they tend
to adopt sensible enhancements to
assure director professionalism and
to facilitate transformation to an
accountable care system.
This model likely has a parent board
with broad-based composition
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drawn from the communities served.
Competency-based succession planning
for the board is more rigorous and
ongoing than it is on most boards
today, but most trustees still come from
the community served. Diversity is a
higher priority, and at least a majority
of board members meet the IRS
independence test. The board may
include several staff physicians who are
selected using the same competencybased criteria and selection process as
any other trustee rather than as medical
staff representatives.
An active working committee structure
engages trustees and other leaders;
committees do the heavy lifting for
the board’s core responsibilities (eg,
finance, audit, compliance, quality,
community benefit, governance).
Subsidiary boards may be eliminated or
retained in advisory and/or community
connectedness roles.
As each board envisions its ideal
governance model for the future, it
is likely to adopt a hybrid of the 3
prototypes, drawing relevant attributes
from each model to construct
its desired “board of the future.”
Professional boards, for example,
select trustees based on particular
competencies but still may look to
their service areas for trustees with
connections or philanthropic ability.
Like professional boards, communitybased boards will expect more from
their trustees and focus more time on
strategy, and clinical enterprise boards
will draw elements from both models.
Best Practices Will Be Widely Adopted
Structural reform alone is not enough.
The literature on effective governance
has grown exponentially in recent years.
As evidence mounts regarding which
practices are truly connected with
better performance for the organization
and board, boards must move from

viewing best practices as aspirational
to making them standard governance
procedure. Some practices are
particularly important to care system
transformation and will apply across
multiple models of future governance.
These include:
• CEO support: Recognizing that a
CEO who wants an informed and
engaged board and actively supports
its work is essential to highperforming governance, boards will
explicitly select and evaluate CEOs
for this attribute.
• Expert competency: Board
composition will include at least
1 independent expert in each of
the board’s core responsibilities;
notably, finance, quality, executive
leadership, and audit. Boards also
will include new backgrounds
and skills consistent with being
an accountable care system (eg,
expert knowledge and leadership
experience in population health
and enterprise risk management).
Lacking sufficient expertise locally,
smaller community boards may
need to broaden their outreach.
• Quality: Boards will elevate
quality to strategic priority status
that requires planning as well as
oversight. They will expand their
purview to embrace the Triple Aim:
improving the patient experience,
the per capita cost of care, and
the health of communities or
populations. They will adopt the
board practices that evidence
indicates are connected with
higher performance by the board,
the organization, or both. These
include spending at least 20% of the
board meeting time substantively
discussing quality performance,
using a board quality subcommittee
to perform more in-depth oversight
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than the full board can, reviewing
a dashboard of quality indicators
regularly, setting quality objectives
for the CEO’s performance
evaluation, and participating with
medical staff leaders in establishing
quality and patient safety goals.1-3
• Transformational leadership: Boards
will draw on a range of leadership
tools that are suited to leading change
and transforming organizations in
an uncertain economic environment.
These include:
– devoting 75% or more of board
meeting times to substantive
interaction on strategic issues rather
than passively listening to reports
– embracing “generative governance
concepts” to identify and explore
questions that unearth new thinking
in board discussions4
– adopting scenario-based and “what
if ” strategic planning methods
– employing bifocal metrics, focusing
on 2 sets of metrics simultaneously:
(1) keeping tabs on current
performance, and (2) tracking
progress toward long-term goals
– using enterprise risk management
techniques to assess the many types
of risk that exist in a changing
environment (ie, financial, strategic,
regulatory, reputational).
• Community benefit: As a matter
of both mission and economics,
boards will devote increased
attention to community benefit,
community health improvement,
and elimination of health
disparities as strategic priorities.
• Capacity for collaboration: Boards
must strengthen their capacity
(continued on page 8)

This newsletter was jointly developed and subject to editorial review by Jefferson School of Population Health and Lilly USA, LLC, and is supported through funding by Lilly USA, LLC.

8

Prescriptions for Excellence in Health Care

for trust and collaboration as
care systems pursue their aims in
cooperation with organizations
outside of their control (eg,
accountable care organizations,
medical homes, public health
agencies, private insurance plans.)
• Board self-evaluation: Boards
will link board evaluation with
specific board improvement plans.
They also will adopt an individual
director assessment process to
reinforce performance expectations
by providing directors with
constructive feedback and by

using evaluations to make
reelection decisions.
Capacity for Self-Assessment
and Improvement
Boards that have established a culture
characterized by accountability, trust,
collaboration, candor, engagement,
continuous learning, and selfassessment will be well equipped to
consider their need to enhance or
overhaul their structure and practices.
For boards that have not reached this
point, the journey to a new governance
model will be more challenging.

Barry S. Bader is President of Bader
& Associates, Healthcare Governance
Consulting. He can be reached at:
barry@baderassociates.com.
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Using Quality and Safety Data for Board Engagement That Makes a Difference in
Patients’ Lives
By Stephen R. Grossbart, PhD
Currently the largest health system and
the fourth largest employer in Ohio,
Catholic Health Partners (CHP) is one
of the largest nonprofit health systems
in the United States, with more than
100 provider organizations that meet
the health care needs of people in
Ohio, Kentucky, and contiguous states.
Operating under a decentralized
model, CHP’s approach to governance
and management balances decisions
made at the local level with those
made at the combined system level.
Although each of CHP’s 7 regional
health systems has its own board of
trustees, all are ultimately accountable
to the CHP board of trustees.

Though CHP was an early adopter of
health care governance, initially QPS
committee meetings dealt primarily
with performance improvement project
updates, crude performance dashboard
reviews, and issues such as Joint
Commission readiness. It was not until
2002 that quality objectives were added
to the system-wide annual plan.

In 1999, CHP was part of a small but
growing number of health systems that
recognized the need to elevate quality
to the same level of governance as other
aspects of health system operations.1
CHP’s board of trustees decided to
create a board quality and patient
safety (QPS) committee 5 years before
the National Quality Forum (NQF)

Today, all members of the CHP
executive management team,
including regional chief executive
officers (CEOs) for the hospital
system, are held accountable for
meeting the quality performance goals
of the annual plan. In retrospect,
“top quartile” targets such as use
of angiotensin-converting enzyme

published Hospital Governing Boards and
Quality of Care: A Call to Responsibility,
encouraging hospital governing boards
to become actively engaged in quality
improvement and focusing attention
on the relationship between governance
and quality of care.2

inhibitors for heart failure patients and
timely use of antibiotics for pneumonia
patients started CHP on a journey
toward elevating the importance of
QPS for the organization’s largely
nonclinical administrative leadership.
Quality Measurement
After becoming a member of the NQF
in 2002, CHP made a policy decision
to use measures endorsed through
NQF’s consensus development process
whenever possible. In addition,
the system formally embraced the
Institute of Medicine’s Quality Chasm
report as its framework for quality
improvement,3 linking objectives and
associated measures to the report’s
6 aims. Consistent with the work of
Berwick et al,4 CHP embedded a clear
distinction between “measurement for
accountability” and “measurement for
process improvement” in its boardapproved policy on quality reporting
and oversight. CHP adopted NQF’s
Safe Practices5 at about the same time.
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Measurement System
Originally, CHP’s decentralized model
did not provide corporate staff with direct
access to quality data. This changed
with the gradual implementation of a
system-wide decision-support system,
computerized physician order entry,
and an electronic health record at all
ambulatory and hospital sites. This
centralized information system is
critical to providing timely information
to the board and giving staff the data
analytic ability to understand variances.
Today, the board views information that
typically is harvested through the month
prior to meeting.
Executive Accountability
CHP has set incrementally higher
expectations for its senior team to meet
QPS objectives. In 2002, only 10% of
the total number of system objectives
focused on quality and safety. Today, over
half of the system goals are directly tied
to QPS. Each objective has equal weight
in determining executive compensation.
The board also requires the system to
meet 3 threshold targets in the areas
of finance, community benefit, and
quality. Today, hospitals must meet a
minimum performance threshold for
patient experience to be eligible for any
incentive compensation. Seven of CHP’s
22 hospitals did not meet this target in
2012 and their leadership teams did not
receive bonuses.
The board QPS committee regularly
reviews data to ensure that performance
levels meet minimum expectations and
patients are not at risk of imminent
harm. If data analysis reveals an issue or
if significant patient events occur, the
QPS committee may place any hospital
or entity on “oversight,” an action that
requires the regional CEO to attend
a QPS committee meeting to outline
an action plan to achieve minimum
performance levels or eliminate the risk

of patient harm. In addition, the regional
board of trustees is updated on the reasons
for the oversight. Three hospitals have
been placed under the oversight of the
CHP board QPS committee since 2009.
Boards on Board Campaign
A significant change for CHP came
about as a result of the Institute for
Healthcare Improvement’s (IHI) 5
Million Lives Campaign, at which time
CHP embraced the IHI’s Boards on
Board campaign (ie, began to provide
educational sessions to members of the
system board of trustees and regional
boards, and encouraged all regional boards
to adopt the campaign planks). 6, 7
The IHI campaign called upon boards
to understand 6 key steps to improving
governance: (1) setting aims, (2) getting
data and hearing stories, (3) establishing
and monitoring system-level measures,
(4) changing the environment, policies,
and culture, (5) learning…starting with
the board, and (6) establishing executive
accountability. At that time, the board
QPS committee had already set aims,
established a monitoring system, and
held senior system leaders accountable
for quality performance, though many
in the organization still believed finance
trumped quality. In response to IHI’s
emphasis on the need for culture
change, the committee’s priorities
shifted toward stories of patient harm
and changing the environment, policies,
and culture of the organization.
CHP’s culture transformation began
with tracking and reporting the rate of
serious reportable events (SREs) based
on the NQF definition.8 Hospital
presidents were trained to make patient
safety walk rounds, and the system
CEO began to join individual hospital
presidents on their walk rounds. The
system adopted “just culture” principles
and conducted its first Agency for

9

Healthcare Research and Quality
Patient Safety Culture Survey in 2005.
A dramatic step toward changing culture
was storytelling around tragic events
involving patient harm. After hearing a
story of patient harm at its April 2008
meeting, storytelling by a regional CEO
or hospital president became a required
agenda item at virtually every board
QPS committee meeting.
Presentation of Data and Information
CHP has developed increasingly
sophisticated mechanisms for sharing
information with its board and
QPS committee at multiple levels.
Reviewed at every meeting, a highlevel dashboard identifies performance
at system, regional, and facility levels,
and provides information on multiple
goals. For 2012, the dashboard tracked
year-to-date performance on systemlevel goals: (1) eliminate preventable
harm, (2) reduce mortality, (3) improve
patient experience, (4) reduce length
of stay, (5) reduce readmissions, (6)
improve emergency department
median admit time, (7) patientcentered medical home recognition,
and (8) achieve CMS Partnerships
for Patients goal to reduce hospitalacquired conditions.
The board QPS committee also is
provided with a detailed drill down
on each goal as well as a control chart
(Figure 1). Eliminating preventable
harm has been a system objective since
2010. Of the 5 harm measures tracked
by CHP, reducing hospital-acquired
falls and trauma with harm has proven
most difficult to achieve. Quantitative
data can be presented in many ways,
enabling clinical staff to inform the
QPS committee that:
•C
 HP’s rate of patient falls with
injury, an NQF SRE, has decreased
(continued on page 10)
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2.5-fold since 2008, from a rate of
0.637 falls per 1000 to 0.261 falls
per 1000.

Figure 1. Proportion of Patients with Falls or Trauma

•T
 his is substantially below the
national average of 0.564 falls
per 1000 reported in the CMS
Hospital Compare database.
•F
 all rates have dropped below the
historical average for 9 consecutive
months beginning in September
2011, representing a statistically
significant improvement.
One might ask, does the board need to
know anything else about falls or should
the staff be congratulated? If the staff was
content, they would be failing to fully
inform the board. In addition to reporting
rates of falls, CHP shares the number of
injuries that occur in our hospitals:
•F
 alls are an NQF SRE defined as
“largely, if not entirely, preventable
and serious.”
• I n 2008, a total of 104 patients
fell and injured themselves in our
hospitals, an average of 9 patients
a month.
• I f trends during the first 8 months of
2012 hold, then 53 patients will suffer
a fall with injury, about 4.4 per month.
•O
 ver 25% of the hospitals in the
United States report no falls.
•N
 ine of CHP’s 22 acute care
facilities have had zero falls
through August 2012.
•E
 vidence-based practices have been
shown to reduce or eliminate the
risk of falls; not all our hospitals
adhere to these practices.
This additional information helps the
board place what initially appears to be
robust performance in the appropriate

Figure 2. Failures of Care Report
Sexual Assault
Eugene - 28 year old Male

Surgery performed on
wrong body part
Ada - 15 year old Female

Eliminate
Preventable Harm

Medication Error
Benjamin- 54 year old Male
Precious - 82 year old Female

Fall
Jill - 33 year old Female
Mary - 76 year old Female
Hannah - 82 year old Female
Curtis - 85 year old Male
Lynn- 89 year old Female
Henry - 82 year old Male
John - 83 year old Male
Anne - 82 year old Female
Dorthy - 73 year old Female
Sharon - 60 year old Female
Katerine - 65 year old Female
Joan - 92 year old Female

Retained Foreign Object
Max - 67 year old Male
Rita - 26 year old Female

2009 - 139 Serious
Reportable Events

2010 - 120 Serious
Reportable Events

context. To put a human face on these
data, CHP developed a quarterly “Failures
of Care” report that highlights the impact
of harm at a human level (Figure 2).
System-wide Adoption of Best Practices
In 2012, CHP corporate QPS staff
requested that each region share its
Failures of Care report with local boards
of trustees. Noting that best practices
adopted at the system level had not
been adopted consistently among the
regional boards, the system’s executive
management team requested that all
regional CEOs begin to share stories
consistently as outlined in the Boards on

2011 - 100 Serious
Reportable Events

2012 - 18 Serious Reportable
Events - as of 3/31/2012

Board campaign and to share the Failures
of Care report quarterly.
Inconsistency in adoption of best
practices across a system is not unique. As
demonstrated by Jha and Epstein, “fewer
than half of the boards rated quality
of care as one of their 2 top priorities,
and only a minority reported receiving
training in quality.”9 This is little changed
from Joshi and Hines’ finding in 2006.10
Conclusion
Six years since the launch of the Boards
on Board campaign, many hospitals
have yet to implement the necessary
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cultural changes, measurement systems,
and governance changes to achieve the
goals of the 5 Million Lives Campaign.
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The Future of Governance: Health Care Boards Change with Challenging Times
By F. Kenneth Ackerman, FACHE, FACMPE
Health care is arguably the most rapidly
changing industry in America. These
are turbulent times for boards and chief
executive officers (CEOs) who face
difficult issues and mounting uncertainty.
Unless the health care enterprise is a
sustainable business model, even the best
governance cannot assure success. The
crucial question facing boards today is
whether the health care enterprise can
transform itself fast enough to succeed in
the face of all this turbulence.
In preparing for this article, 25
health care industry leaders with over
1000 years of collective governance
experience were interviewed. Ten
themes emerged from these interviews.
1. Health care boards will continue to
become smaller
An important change in governance of
nonprofit hospitals and health systems
will be in the size of boards. According
to the American Hospital Association,
most boards today have between 15 and
18 board members, and some of the

largest ones have 30 or more directors.
Many of these boards are still too big to
assure effective governance.
Smaller boards lead to a
greater sense of ownership and
accountability. Members come to
meetings better prepared and feel
more satisfaction in their board
service. Smaller boards are less
cumbersome decision makers and
take action more promptly when it
is needed.
2. Boards will govern larger and more
complex clinical enterprises
Consolidation in the industry will
continue to accelerate for one simple
reason: scale matters. In addition
to economic pressures, there are
other compelling forces requiring
hospitals and health systems to
manage the entire continuum of
care. The visionary health care
enterprise is already focusing on
managing the health of entire
defined populations.

We are witnessing a transformation
in the way health care is delivered
in this country, one that is driven by
the simple reality that health care
costs are growing at a rate that is
unsustainable. This transformation
will be a catalyst that ultimately
requires boards to significantly
upgrade their own performance.
3. Boards will need to understand and
manage risk
With the growing complexity of health
care systems comes increased risk in
several areas — strategic, operational,
financial, and compliance. In addition
to regulatory risk more risk will arise
from the growth and complexity of the
enterprise, the challenge of physicianhospital integration, quality issues,
the expanded use of electronic health
records while meeting Health Insurance
Portability and Accountability Act
privacy and security requirements,
increasing reliance on outsourcing,
and other factors. Environmental,
economic, political, regulatory, and
(continued on page 12)
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social landscapes are in a state of flux. At
any given moment an unexpected crisis
can demand an immediate response.
The responsibility for risk oversight
lies with the full board of directors.
Boards will need to develop a clear
understanding of the risks they face
and avoid, mitigate, or monitor them.
Risk scenario planning will become
commonplace on good boards.
Because many risks can be “value
killers,” or “reputation killers,” they
require constant vigilance. Board
members must continually ask
themselves, “What don’t we know that
we should know?”
4. Board composition will change
Hospitals and health systems will
focus more on the clinical enterprise,
becoming obsessed with outcomes,
quality, and safety. More of these
organizations will be led by physician
CEOs. Good governance requires
independent directors with the right
skill sets and expertise to make difficult
decisions. More boards will look outside
their communities to find directors
with the requisite backgrounds,
including industry experts (eg, physician
executives, nurse executives, marketing
executives, chief information officers,
health insurance executives).
The right board composition for any
organization is driven by the vision and
strategy of the enterprise.
5. Boards will become more diverse
It is important to have a mix of
perspectives on any issue. Racial, gender,
and ethnic diversity helps to assure
robust boardroom discussions when
dealing with the strategic imperatives
of the enterprise. If diversity doesn’t
start with the board, it is often difficult
to assure adequate diversity throughout
the organization. However, finding

directors with the appropriate skills and
experience will remain the top priority.
6. Boards will become more transparent
Outside pressures, including the
new Internal Revenue Service form
990 and its schedule H, state and
federal governments, and aggressive
states’ attorneys general — all in
an environment with Internet
and 24/7 media attention — will
drive organizations toward greater
transparency. The public demand for
higher quality, safety, and customer
service create a need to demonstrate
the “value proposition” for community
wellness, disease prevention, better
health outcomes, and lower costs. Also,
transparency builds trust both inside and
outside the organization.
7. CEO succession will become a priority
Despite the fact that CEO turnover has
remained alarmingly high for the past
decade, fewer than 20% of boards have a
good succession plan in place. The lack
of a formal succession plan heightens
the possibility that the organization will
need to recruit the next CEO from the
outside, an option fraught with risk of a
costly failure.
Succession planning is a fundamental
responsibility of the board. Successful
transitions require careful planning by
the board and the CEO.
8. Best practices will become the norm
The current health care environment —
with changing regulations, pressure from
ratings agencies and payers, liability
risks, rising public expectations, and the
potential for public embarrassment if
something goes wrong — is best dealt
with by adhering to best practices.
Sophisticated boards will constantly
measure everything, including their own
performance. They will conduct annual
CEO appraisals, annual appraisals of

board and committee chairs, reviews of
board and committee performance, and
peer- and self-evaluations of directors.
Intentional self-examination over a
sustained period will help improve
board performance.
9. Highly qualified directors will be difficult
to find
Board work today requires significantly
more time than it did 10 years ago.
Although there are rewards for board
service there are drawbacks as well,
including the rigors and risks of board
membership, the travel and preparation
time required, and concerns about
personal liability and reputational risk.
Other factors (eg, retirement of baby
boomers, scarcity of CEOs willing
and able to sit on outside boards ) are
reducing the pool of candidates for
board membership.
The best boards are already thinking
outside the box, expanding their search
parameters, and looking outside their
own communities to find well-qualified
candidates to fill board positions. The
use of professional search firms to
identify qualified board members will
become common practice.
10. More large health system boards will
compensate directors
The importance of finding the right
candidate, an acknowledgement of
the time requirements placed on
board members, and the growing
recognition that highly-qualified
candidates have many opportunities
to serve on other boards are among
the primary reasons why many
large health systems will consider
compensating board members.
Although director compensation
is controversial, real value lies in
the social contract that such pay
establishes between the board and
the organization. Boards must
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weigh the decision to compensate
directors carefully to determine
whether it is the right decision for
their particular situation.
Summary
The next 10 years will be a difficult
time to serve on the board of a health
care provider organization. Boards will
need wisdom and courage to keep their
organizations on the right course. They
will need to follow governance best
practices to demonstrate to a wary public
that they are acting in the best interests
of the patients and the communities
they serve. They will need to deal
with issues such as CEO turnover,
physician integration, revenue and
capital constraints, quality and safety
issues, and mounting risks in governing
bigger and more complicated enterprises
— all in the face of changes in the
environmental, economic, political,
regulatory, and social landscapes.
To meet the challenges of the future,
boards must begin to operate differently

than they did in the past by adopting
best practices, recruiting directors
carefully, being proactive and transparent,
and making decisions quickly. Good
governance will be essential to assure a
high-performing health care enterprise
in these challenging times.
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Board Size and Composition in Large Nonprofit Health Systems
By Lawrence Prybil, PhD, LFACHE
A recent study examined board
structures, processes, and cultures in a set
of the country’s largest nonprofit systems
and compared them to benchmarks of
effective governance.1 The 4 phases of
the methodology employed to gather
and analyze information have been
published previously.2
Summary of Findings Regarding Board
Size and Composition
Board Size
Neither in the health care field nor
other sectors is there an exact answer to

the question, “How large should
a board of directors be?” The 2007
report of the Center for Healthcare
Governance Blue Ribbon Panel on
Healthcare Governance advocated a
range of 9 to 17 voting members for
hospital and health system boards.3
Several other authorities have offered
similar recommendations.
For 10 of the 14 systems, board size is
consistent with the Blue Ribbon Panel’s
recommendation. Three boards have
between 18 and 28 voting members;
1 board has 60 members. The median

size is 15 members, excluding the
outlier with 60 voting members.
The boards of these systems are somewhat
larger than the boards of our country’s
hospitals and health systems as a whole
(whose average size consistently has been
between 12 and 14 since 2005) and the
boards of our country’s public companies
(whose average size has remained in the 8
to 9 range for many years).1
Board Composition
Independence. The Sarbanes-Oxley
Act of 2002 made the definition
(continued on page 14)
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of “independence” more stringent
and increased the requirements for
independent board members on the
boards of public companies. The
impact on the composition of public
company boards has been striking. The
proportion of independent directors on
the boards of Fortune 500 companies
increased from 22% in 1987 to 84% in
2011.4 Although the Sarbanes-Oxley
Act applies only to public companies,
many of its key provisions have been
adopted voluntarily by nonprofit
hospitals and health systems. Several
authorities, including the Internal
Revenue Service, have called for a
majority of board members in nonprofit
organizations to be independent.
For the purpose of this study, the
term “independent board member”
was defined as persons who are “not a
member of a sponsoring body such as a
religious congregation, not a full- or parttime system employee, and not directly
affiliated with the system in any way
except serving as a voting board member.”
Table 1 shows that, in total, 60% of the
members of the 14 system boards in this
study population meet these criteria.
However, 82% of board members in the 5
secular health systems meet the criteria for
independence — virtually identical to the
current composition of America’s public
companies — while only 49% of faithbased system board members meet those
criteria. Clearly, the composition of most
faith-based system boards still includes
a substantial proportion of persons
who are affiliated with the previous or
current religious sponsors. The range of
independent member composition varies
from 18% for 1 faith-based system to
100% for 1 secular system, the single
system in which the CEO is not a voting
member of the board.
Diversity. In the health care field
and other sectors, there is agreement
that governing boards must include
persons with a strong blend of pertinent

experience and skills in order to perform
their fiduciary duties effectively. It
is increasingly recognized that the
boards of nonprofit organizations also
should include members with diverse
backgrounds and perspectives.
Table 2 shows the proportion of
nonwhites serving on the boards of
the 14 large systems in this study
population. In total, 17% of the systems’
board members are nonwhite; the
proportion of those serving on faithbased vs. secular boards is virtually
identical. This is somewhat higher
than the comparable figure (10%) for
hospitals that participated in a 2011
survey conducted by the American
Hospital Association (AHA).5
Table 3 shows the gender mix of the
14 systems’ boards. Although there is
some variation from board to board, the
overall proportion of women serving on
the boards of the 9 faith-based systems
(40%) is significantly higher than the
corresponding figure for the secular
systems (21%). Collectively, hospitals

and health systems that participated in
a nationwide survey by the Governance
Institute in 2011 reported that 26% of
their board members were women.6
As compared to America’s Fortune
500 companies, the boards of these
14 large, nonprofit health systems are
more diverse, both in racial and gender
composition. In 2011, only 14% of
Fortune 500 board members were
nonwhite and only 16% were women.4
It appears that our nation’s largest
nonprofit health systems are responding
to what is, on balance, a compelling case
for diversity in board composition.
Clinical Engagement. The National
Quality Forum and other prominent
health care organizations have urged
hospital and health system boards to
engage clinical leaders in developing
strategies to improve patient care quality
and safety. Involving highly qualified
physicians who are committed to
the organization’s mission has become
a standard governance practice. The
findings of several national studies in

Table 1. Independent vs. Non-Independent Board Members
Board Composition Board Composition Board Composition
in Faith-Based
in Secular Systems in All Systems
Systems (n = 179)
(n = 95)
(n = 274)
Independent

49%

82%

60%

Non-Independent 51%

18%

40%

P < .01*

100%

100%

100%

*The chi-square test demonstrates significantly different proportions of independent board members in faith-based systems.

Table 2. Racial Composition of Large System Boards
Board Composition Board Composition Board Composition
in Faith-Based
in Secular Systems in All Systems
Systems (n = 179)
(n = 95)
(n = 274)
Nonwhite
Members

17%

18%

17%

White Members

83%

82%

83%

N/S*

100%

100%

100%

*The observed differences were not statistically significant
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recent years show physicians generally
constitute approximately 20% of hospital
and health system board membership.
In contrast, engaging nursing
profession leaders in the governance of
health care organizations traditionally
has not been a common practice.
Studies completed in 2005 and 2009
found that nurses comprised only
about 2% of nonprofit hospital and
community health system boards.7,8
Recognizing the vital role of nursing
in determining the quality and cost of
care, a growing number of respected
organizations including the Robert
Wood Johnson Foundation have urged
hospital and health system officials to
consider the appointment of highly
qualified nurse leaders to their boards.
Table 4 shows that, in combination,
14% of the study populations’ board
members are physicians and 6% are
nurses. Physicians are somewhat more
prominent on the boards of secular
systems (18%) as compared to faithbased systems (11%); nurses comprise
a larger proportion of the faith-based
system boards (9%) than the secular
system boards (2%). In both groups,
clinicians collectively constitute 20% of
the systems’ voting board membership.
The finding that 6% of large system
board members are nurses is exactly
consistent with the results of the AHA’s
2011 survey of American hospitals.5
These findings appear to represent a
shift in the direction that Hassmiller
and Combes, and others believe is “…
long overdue.” 9
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Table 3. Gender Composition of Large System Boards
Board Composition Board Composition Board Composition
in Faith-Based
in Secular Systems in All Systems
Systems (n = 179)
(n = 95)
(n = 274)

Women

40%

21%

33%

Men

60%

79%

67%

P < .01*

100%

100%

100%

*The chi-square test demonstrates significantly different proportions of women board members in faith-based vs. secular systems.

Table 4. Clinician Composition of Large System Boards
Board Composition Board Composition Board Composition
in Faith-Based
in Secular Systems in All Systems
Systems (n = 179)
(n = 95)
(n = 274)
Nurses

9%

2%

6%

Physicians

11%

18%

14%

Other

80%

80%

80%

100%

100%

100%

P < .05

*

*The chi-square test demonstrates significantly different proportions of nurses in the board compositions of faith-based vs.
secular systems.

Conclusion
With respect to board size and
composition, the boards of these large
systems are somewhat more consistent
with current benchmarks of effective
governance than the country’s hospitals
and health systems as a whole. The
board leaders and CEOs of these
systems are encouraged to continue
their efforts to identify opportunities
to improve their governance model and
performance.
Lawrence Prybil, PhD, LFACHE, is
Norton Professor in Healthcare Leadership
and Associate Dean, College of Public
Health, University of Kentucky. He can be
contacted at Lpr224@uky.edu
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